Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 13/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132043 | 1.00 | LAP3 (0.46) | LAP3FDPSLMNAGGPS1METAP1 | |
| SCHEMBL6665925 | 0.82 | FDPS (0.50) | LAP3FDPSGGPS1METAP1 | |
| SCHEMBL5262879 | 0.79 | FDPS (0.61) | LAP3FDPSGGPS1 | |
| SCHEMBL5054818 | 0.78 | ANPEP (0.44) | LAP3FDPSLMNAGGPS1ADRB3 | |
| SCHEMBL5054803 | 0.78 | FDPS (0.41) | LAP3FDPSLMNAGGPS1ADRB3 | |
| SCHEMBL28358931 | 0.76 | FDPS (0.41) | LAP3FDPSLMNAADRB3PDE4D | |
| SCHEMBL8591903 | 0.76 | FDPS (0.68) | LAP3FDPSGGPS1 | |
| SCHEMBL28355348 | 0.76 | FDPS (0.41) | LAP3FDPSGGPS1METAP1 | |
| SCHEMBL28440465 | 0.73 | LAP3 (0.43) | LAP3FDPSMETAP1 | |
| SCHEMBL28358933 | 0.73 | FDPS (0.38) | LAP3FDPSLMNAMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | LAP3 1400/4885FDPS 1920/4885LMNA 1103/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | LAP3 1256/4885FDPS 4116/4885LMNA 2481/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | LAP3 1185/4885FDPS 4229/4885LMNA 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.